Homebrandadmin2020-09-14T08:56:58+00:00

WELLSTAT THERAPEUTICS CORPORATION

Discover, develop and commercialize products that will provide new and improved treatments for patients in the fields of oncology, metabolic, neurometabolic and neurodegenerative diseases.

Learn More

COMPANY OVERVIEW

Wellstat Therapeutics Corporation is a privately-held biopharmaceutical company located in Rockville, Maryland. Dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontiers of medicine, Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases.

Wellstat Therapeutics’ focus is in the following fields:

ONCOLOGY

METABOLIC DISEASES

NEURODEGENERATIVE DISEASES

NEUROMETABOLIC DISEASES

Wellstat Therapeutics is developing an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics’ pipeline spans the stages of development from discovery through Phase III clinical trials.
Wellstat Therapeutics’ predecessor company was founded in 1985.

The Company has a highly talented management team with significant experience in drug discovery, development, and commercialization. Samuel J. Wohlstadter, a company founder and the Chief Executive Officer was also a founder of Amgen Inc., Applied Biosystems (currently owned by Thermo Fisher Scientific), IGEN International Inc. (currently a subsidiary of Roche), BioVeris Corporation (currently a subsidiary of Roche), and Hyperion Catalysis International, Inc.

Wellstat Therapeutics employs dedicated scientists, business professionals and support personnel at its state-of-the-art facilities in Rockville, Maryland. Wellstat Therapeutics is part of the Wellstat Group of Companies, one of the leading bioscience employers in the Baltimore-Washington Metropolitan Area. The Wellstat Group of Companies has expertise in all stages of discovery research and development, including:

Chemistry
Cell and Molecular Biology
Disease Models
Translational Biology
Clinical Research and Development
Project Management
Regulatory Quality Assurance and Control
Manufacturing
Legal and Financial

Wellstat Therapeutics has two approved products,
Xuriden® and Vistogard®

For product medical information, please send an email to medinfo@wellstat.com or call 1-800-914-0071.

VISIT XURIDEN.COM
Full Prescribing Information

VISIT VISTOGARD.COM
Full Prescribing Information

Research & Development

Wellstat Therapeutics is developing an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics’ pipeline spans the stages of development from discovery through Phase III clinical trials.

Wellmond, a division of Wellstat Therapeutics, has a diverse pipeline which includes FDA-approved products and development-stage therapies based on our proprietary uridine product platform.

Click on each compound name to learn more

Mitochondrial diseases are caused by genetic defects in the function of mitochondria, subcellular organelles involved in the production of energy from food-derived fuels and oxygen. Mitochondrial diseases therefore often affect tissues with a high energy demand, including the heart, central nervous system and muscles. WT501 is active in models of mitochondrial diseases, regardless of the specific molecular defect in the mitochondrial respiratory chain, and has been provided to a limited number of patients on a compassionate use basis. Clinical trials for this indication are planned.

WT501 is also active in models of Alzheimer’s, Huntington’s, and Parkinson’s diseases, which all involve mitochondrial dysfunction as a key feature in their pathogenesis. This investigational compound may address the metabolic dysfunction that is a commonly shared factor in the pathology of these disorders.

Gout attacks are caused by formation of crystals of uric acid in joints, and may be prevented by treatments that reduce concentrations of uric acid in plasma. WT2107 is a novel oral agent for uric acid lowering that in preclinical models appears may be more active than other agents.

Inflammatory skin diseases, such as psoriasis and atopic dermatitis, are relatively common and are still inadequately addressed with topical treatments. WT35023 is a novel anti-inflammatory agent that may selectively disable pathologically activated macrophages, key cells underlying tissue damage in inflammatory and autoimmune diseases, and has shown strong activity in preclinical models of psoriasis.

One of the most consistent changes in invasive solid tumors versus normal cells is a change in lysosomal characteristics, yet few drugs exploit this difference. In preclinical models, WT35021 selectively kills tumor cells by targeting the lysosomal phenotype characteristic of invasive cancers.

Serious systemic fungal infections are major problems in patients with suppressed immune systems, whether due to anti-rejection drugs used in organ transplants or to HIV. WT39006 uniquely attacks a fungal target critical for growth of both yeast and filamentous fungi. Clinical targets include Cryptococcus, which kills more than 600,000 people per year, as well as Aspergillus and Candida infections.

Contact Us

Wellstat Therapeutics Corporation
14200 Shady Grove Road, Suite 600
Rockville, MD 20850, USA

Phone: +1 240-631-2500
Fax: +1 240-683-3793
Email: inquiries@wellstattherapeutics.com

Careers

Disclaimer